| Registry | NCT02848937, acronym CITRUS |
|---|---|
| Status | Unknown |
| Study type | Observational |
| Enrollment | 62 (Estimated) |
| Sponsor | Azienda Ospedaliera, Ospedale Civile di Legnano (Other); collaborators: AO Garbagnate-Bollate |
| Conditions | ESRD |
| Interventions | Bath with citrate, Bath with citrate and Ca_eq (Device) |
| Dates | start 2013-03-01, primary completion 2016-07-01, completion 2016-12-01 (estimated), first posted 2016-07-29, last updated 2016-07-29 |
| Locations | 1 site in Italy |
Related Papers Related Patents Related Grants Related Experts
All trials for ESRD All trials of Bath with citrate All trials of Bath with citrate and Ca_eq
This study aimed to evaluate the effect on the calcium balance of a concentrate with 1 mM citrate and locate the equivalent concentration of calcium (Ca_eq) at a concentration of 3 mM acetate and traditional with 1.5 mM calcium in HD. The secondary objective is to evaluate the performance in the medium term of purifying the concentrate with 1 mM citrate and Ca_eq, compared to traditional concentrated with 3 mM acetate and 1.5 mM calcium in HD.
Primary Objective The primary objective of this study is to find the formulation of calcium (1.50, 1.65 and 1.75 mM) in the bath with 1 mM citrate which allows the equivalence of calcium balance (Ca_eq) in a sitting HD compared to traditional concentrated with 3 mM of calcium acetate and 1.5.
Secondary objectives
* Evaluate the purifying performance of small and medium-sized molecules in HD with concentrated with 1 mM citrate and Ca_eq compared to traditional concentrated with 3 mM calcium acetate and 1.5.
* Observe the effects on hemodynamic of the concentrate through the variation of the pre and post-dialysis blood pressure and intradialytic symptoms (cramps, hypotension, headache).
* Evaluate the variations of the parameters of mineral metabolism: Predialytic values of PTH, alkaline phosphatase treatments with concentrated Cit (1 mM citrate and Ca_eq) and concentrated with traditional Ac (3 mM calcium acetate and 1.5).
| Arm | Type | Interventions | Description |
|---|---|---|---|
| Bath with citrate | Device: Bath with citrate | Each patient will participate in two phases of the study. The first phase has the aim to identify the concentration of calcium in the bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium (4 weeks). Each week, the concentration of calcium in the bath with citrate is increased from 1.5-, to 1.65, to 1.75 mM. •Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates.•All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study | |
| Bath with citrate and Ca_eq | Device: Bath with citrate and Ca_eq | Each patient will participate in two phases of the study. In the second phase will evaluate the effectiveness of the purification concentrate with 1 mM citrate and Ca_eq compared to the concentrate with 3 mM acetate and 1.5 mM calcium. For each of the sessions will be used the following materials: * Filter high permeability (Kuf> 20ml/mmHg); * Concentrate SelectBag One (with 3 mM acetic acid) and SelectBag Citrate (with 1 mM of citric acid). The potassium in the bath will be chosen on the basis of the needs of the patient (2 to 3.5 mM) and will be maintained in all concentrates. * All treatment parameters (Qb, time of treatment, weight loss and anticoagulant dose) should be overlapped at all stages of the study. |
Sex: All, ages: 18 Years to any
Inclusion Criteria: * Patients clinically stable. * age> 18 years. * HD therapy for more than 3 months. * good vascular access native functionality that enables real blood flow of at least 250 ml / min. Exclusion Criteria: * Patients with the features listed below may not be enrolled in this survey: * Life expectancy <6 months. * residual diuresis> 500 ml / day.
| Facility | City | Country | Status |
|---|---|---|---|
| Carlo Maria Guastoni | Legnano, Milano | Italy | Recruiting |